Email the author Effectiveness of COVID-19 Antivirus Therapy and Its Relationship with Vaccination: A Retrospective Analysis
Abstract
Background: COVID-19 is known to have infected more than a million people. COVID-19 can be treated with antivirals. Besides antiviral drugs, vaccination becomes one of the strategies to suppress the spread of COVID-19. This study aimed to analyze the effectiveness of antivirus and the relationship between vaccination and the effectiveness of the two antiviral therapies in COVID-19 patients based on improvements in the patient's clinical condition, length of stay, and mortality.
Methods: This study used a retrospective cohort design conducted at the Universitas Indonesia Hospital, Depok, Indonesia. Data were taken from medical records and hospital databases from January 2021 to August 2022. The antivirals in this study were remdesivir and favipiravir. The samples were divided into two groups, namely the vaccinated and unvaccinated groups.
Results: The factor affecting the effectiveness of remdesivir and favipiravir therapy was the severity of COVID-19. It was shown that vaccination had a significant effect on improving clinical conditions, reducing length of stay, and reducing mortality in patients treated with remdesivir who had been vaccinated compared to those who had not been vaccinated. In patients who received favipiravir therapy and were vaccinated, it also showed an effect on improving clinical conditions, length of stay, and mortality compared to patients who were not vaccinated, although the results were not statistically significant.
Conclusion: Vaccination had a positive effect on the effectiveness of remdesivir and favipiravir in COVID-19 patients, which could improve the patient's clinical condition in a better direction, as well as reduce length of hospitalization and mortality.
Keywords
Full Text:
PDFReferences
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33.
Handayani D, Hadi DR, Isbaniah F, Burhan E, Agustin H. Penyakit virus corona 2019. J Respir Indones. 2020;40(2):119–29.
Alamer A, Alrashed AA, Alfaifi M, Alosaimi B, AlHassar F, Almutairi M, et al. Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysis. Curr Med Res Opin. 2021;37(7):1085–97.
Damayanti H, Sajinadiyasa IGK, Risni HW, Sauriasari R. The Effectiveness and Safety of Favipiravir in COVID-19 Hospitalized Patients at Tertiary Referral Hospital, Bali,Indonesia. Kesmas. 2021;16(4):289–97.
PDPI, PERKI, PAPDI, PERDATIN, IDAI. Pedoman tatalaksana COVID-19: Edisi 4. Indonesia: 4; 2022.
Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the Treatment of Covid-19 — Final Report. N Engl J Med. 2020;383(19):1813–26.
Garibaldi BT, Wang K, Robinson ML, Zeger SL, Bandeen-Roche K, Wang MC, et al. Comparison of Time to Clinical Improvement with vs without Remdesivir Treatment in Hospitalized Patients with COVID-19. JAMA Netw Open. 2021;4(3):1–14.
Mozaffari E, Chandak A, Zhang Z, Liang S, Thrun M, Gottlieb RL, et al. Remdesivir treatment in hospitalized patients with COVID-19: a comparative analysis of in-hospital all-cause mortality in a large multi-center observational cohort. Clini Infect Dis. 2021;2019.
Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering. 2020;6(10):1192–8.
Chen C, Zhang Y, Huang J, Yin P, Cheng Z, Wu J, et al. Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial. Front Pharmacol. 2021;12(September):1–11.
Bernal JL, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: Test negative case-control study. The BMJ. 2021;373.
Mohammed I, Nauman A, Paul P, Ganesan S, Chen KH, Jalil SMS, et al. The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review. Hum Vaccin Immunother. 2022;18(1).
Ramakrishnan M, Prakash S, Nagar J. Impact of vaccination in reducing hospital expenses, mortality and average length of stay among COVID-19 patients – A retrospective cohort study from India. medRxiv. 2021;
Soegiarto G, Purnomosari D, Wulandari L, Mahdi A, Fahmita D, Hadmoko T. Articles Incidence of SARS-CoV-2 infection in hospital workers before and after vaccination programme in East Java , Indonesia – A retrospective cohort study. The Lancet Reg Health - Southeast Asia. 2023;10:100130.
Cucunawangsih C, Wijaya RS, Lugito NPH, Suriapranata I. Post-vaccination cases of COVID-19 among healthcare workers at Siloam Teaching Hospital, Indonesia. Int J Infect Dis. 2021;107:268–70.
BPOM, JICA. Modul farmakovigilans untuk tenaga profesional kesehatan, proyek “ensuring drug and food safety.” Badan Pengawas Obat dan Makanan. 2020;
Marshall JC, Murthy S, Diaz J, Adhikari N, Angus DC, Arabi YM, et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20(8):e192–7.
Olender SA, Perez KK, Go AS, Balani B, Price-Haywood EG, Shah NS, et al. Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care. Clin Infect Dis. 2021;73(11):E4166–74.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020;395(10229):1054–62.
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020;395(10223):507–13.
Hafiz M, Icksan AG, Harlivasari AD, Aulia R, Susanti F, Eldinia L. Clinical, radiological features and outcome of COVID-19 patients in a secondary Hospital in Jakarta, Indonesia. J Infect Dev Ctries. 2020;14(7):750–7.
Pranata R, Lim MA, Yonas E, Vania R, Lukito AA, Siswanto BB, et al. Body mass index and outcome in patients with COVID-19: A dose–response meta-analysis. Diabetes Metab. 2021;47(2):101178.
Kementerian PPN, Bappenas. Buku studi pembelajaran penanganan COVID-19 Indonesia. Jakarta, Indonesia; 2021.
Matrajt L, Brown ER, Cohen MS, Dimitrov D, Janes H. Could widespread use of antiviral treatment curb the COVID-19 pandemic? A modeling study. BMC Infect Dis. 2022;22(1):1–16.
Panagopoulos P, Petrakis V, Trypsianis G, Papazoglou D. Early 3-day course of remdesivir in vaccinated outpatients with SARS-CoV-2 infection. A success story. J Chemo. 2022;34(8):550–3.
Instiaty, Sri Darmayani IGAAP, Marzuki JE, Angelia F, William, Siane A, et al. Antiviral treatment of covid-19: A clinical pharmacology narrative review. Med J Indones. 2020;29(3):332–45.
Tan L, Kang X, Ji X, Li G, Wang Q, Li Y, et al. Validation of Predictors of Disease Severity and Outcomes in COVID-19 Patients: A Descriptive and Retrospective Study. Med. 2020;1(1):128-138.e3.
Tjendra Y, Al Mana AF, Espejo AP, Akgun Y, Millan NC, Gomez-Fernandez C, et al. Predicting disease severity and outcome in COVID-19 patients: A review of multiple biomarkers. Arch Pathol Lab Med. 2020;144(12):1465–74.
Goyal A, Cardozo-Ojeda EF, Schiffer JT. Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response. Sci Adv. 2020;6(47):1–13.
Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020;323(18):1824–36.
DOI: https://doi.org/10.36497/jri.v43i3.434
Refbacks
- There are currently no refbacks.
Copyright (c) 2023 Andi Utari Prasetya Ningrum, Retnosari Andrajati, Nadia Farhanah Syafhan, Aditya Wirawan
INDEXING & PARTNER
| Jurnal Respirologi Indonesia pISSN: 0853-7704 - eISSN: 2620-3162 Address: Jalan Cipinang Bunder No. 19, Cipinang, Pulogadung, Jakarta Timur, DKI Jakarta 13240, Indonesia Phone: +62-21-2247-4845 Email: editor@jurnalrespirologi.org |  An official publication by the Indonesian Society of Respirology (ISR) |
 Creative Commons Attribution-ShareAlike 4.0 International License Statcounter |